RBL2

Across TCGA pan-cancer cohorts, RBL2 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of RBL2’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where RBL2 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types RBL2 is over-expressed in tumor, although a few such as HNSC and LSCC show the opposite, repressed pattern.

HNSC, LSCC, and CCRCC are the cancer types where RBL2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RBL2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	III,IV	−0.167	<.001	8	view →
LSCC	Male	II,III,IV	−0.220	<.001	6	view →
CCRCC	All	II,III,IV	−0.062	.019	2	view →
PDAC	Male	All	−0.231	.049	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

RBL2–HNSC

Open the HNSC breakdown →